ARWRArrowhead Pharmaceuticals, Inc.
Price
+105%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, growing in the filings, the market undecided.
RNA interference (“RNAi”) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. Small molecule and antibody drugs have proven effective at inhibiting certain cell surface, intracellular, and extracellular targets.
In the company’s own words · 10-K filed Nov 25, 2025 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $75M in Q3 2026 (quarter ended Jun 30, 2026), up 171% from the same quarter a year earlier. That came with net loss of $194M. For the full year FY2025, revenue was $829M (+23258% year on year) and net income −$1.6M. The next results filing is expected around Nov 24, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results.Earnings release · press release
- Jun 16, 2026Appointment of Dr. Matt Cohen as a Director On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026.Director or officer change · Form 8-K
- May 7, 2026Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.